AZN vs NVO
AstraZeneca PLC and Novo Nordisk A/S, both Healthcare
AstraZeneca PLC is the larger company at $266B against $173B. Over the past year AZN returned +3.4% against -28% for NVO. The RyuScore puts NVO ahead, 88 against 62 out of 100.
| Figure | AZN | NVO |
|---|---|---|
| Last close | $171 | $39.03 |
| Market cap | $266B | $173B |
| 1-year return | +3.4% | -28% |
| 5-year return | +55% | -12% |
| RyuScoresector-relative, 1–10 | 62/100 | 88/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Novo Nordisk A/S
Open these two in the interactive comparison to add more names, change the period or see the correlation.